tbuckley/cabot-search huggingface dataset:
If your patient doesn’t speak the same language as you . . .
Journal: BMJ (2017)

If your patient doesn't speak the same language as you . . .Sisters SD and ZA offer advice to doctors trying to work well with family translators Anonymous SD: When I came to the UK I was about 11 years old.I began English lessons at school, but at first I couldn't even ask the teacher if it was OK to go to the toilet.So I really do know what it's like being unable to understand what's going on around you.I was the first English speaker in my family, so I translated for my parents at the doctor's surgery and hospital.ZA: I came to the UK when I was in my 20s.Because I started later, it has been much harder for me to speak English than it was for my sister.My sister translates what I say when I go to the doctor.But I do
Predicting survival benefit of capecitabine plus cisplatin in patients with metastatic gastric cancer patients using quantitative proteomics
Authors: D. Yan, M.-H. Ryu, E. An, Y.S. Park, H. Na, J. Ma, Y. Tian, F. Cecchi, T. Hembrough, Y.-K. Kang
Journal: Annals of Oncology (2018)
PRINT: Prostate cancer intensive, non-cross reactive therapy for CRP—Early observations of efficacy.
Authors: Bobby Chi-Hung Liaw, Che-Kai Tsao, Matt D. Galsky, Richard Lorne Bakst, Robert Stewart, Richard Stock, William K. Oh
Journal: Journal of Clinical Oncology (2020)

89 Background: Optimal sequencing of therapeutic agents in mCRPC remains debated, but the standard approach is to treat with one agent until resistance is met before switching. PRINT explores the efficacy of treating mCRPC with a rapidly-cycling, non-cross reactive regimen as a way to more effectively treat intrinsic heterogeneity, delay/prevent drug resistance, and minimize toxicity. Methods: Enrolled patients all received 3 consecutive treatment modules, each 12 weeks: 1. abiraterone acetate 1000 mg PO daily + prednisone 5 mg PO BID; 2. cabazitaxel 20 mg/m2 IV + carboplatin AUC 4 IV q3 weeks; 3. enzalutamide 160 mg PO daily + radium-223 55 kBq/kg IV q4 weeks (in those with bone metastases). Upon completion of the 9-month regimen, patients are followed on ADT alone. Primary endpoint for the study is PSA or radiographic time to progression (TTP). Results: From 3/2017 to 10/2019, 35 of 40 planned men with mCRPC were enrolled, 25 patients have completed the 9-month study regimen and evaluable for TTP analysis. With median follow up of 52 weeks, median time to PSA progression after therapy completion is 15.5 weeks (95%CI; 5-26.1+ weeks). PSA response rates show successive improvements with each sequential treatment module (Table). Six (24%) patients continue on post-study surveillance with ADT alone, two of which have remained off any mCRPC agents for over a year (64+ weeks, 54+ weeks). In patients needing to restart therapy, experience with efficacy and tolerability of each agent while on the study, has helped inform subsequent mCRPC drug selection. The study regimen is well-tolerated, with few grade 3/4 AE’s: hyperglycemia (14.3%), diarrhea (5.7%), anemia (2.9%), fatigue (2.9%), neutropenia (2.9%), and thrombocytopenia (2.9%). Conclusions: Treatment of mCRPC with a rapidly-cycling non-cross reactive regimen demonstrates significant antitumor benefits, with potential for long-term suppression of disease. Further longitudinal follow up will determine if PRINT delays progression compared with standard approaches. Clinical trial information: NCT02903160. [Table: see text]
Liver Disorders in Childhood
Authors: Barbara S. Kirschner
Journal: JAMA (1988)

The second edition of<i>Liver Disorders in Childhood</i>comes eight years after publication of the original text. Many of the topics have been extensively expanded to include updated explanations of normal anatomy and cellular and subcellular function, as well as pathogenetic mechanisms of disease and new diagnostic and therapeutic methodologies. The discussions are accompanied by a large number of excellent summary tables, line drawings, and electron micrographs. Introductory chapters on bilirubin and bile salt formation and secretion and drug metabolism provide a basis for understanding physiological and disease-related perturbations, which are discussed in subsequent sections. The text is highly readable, almost conversational in style, as Dr Mowat shares his extensive knowledge and experience. The format of the chapters tends to follow a consistent pattern, which includes definition, etiology, pathology, clinical features, diagnosis, and management. The discussion of pathogenesis in some sections is perhaps too simplified (hepatic coma). However, the great
Sensitivity and specificity in silicone breast models
Authors: F. E. Gump
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The use of silicone breast models,<sup>1</sup>the better to train physicians in the detection of breast lumps, is well meaning but of uncertain value in clinical care. However, this letter is intended to point out that certain techniques will actually make early detection of breast cancers less effective. The problem with currently available models is that they place "tumors" in a uniform matrix designed to simulate the normal breast. The ability to detect lesions of varying size, depth, and consistency in such a model is irrelevant, and the fact that fingertips (as opposed to pads) proved to be more effective in the present study illustrates this point. Successful breast examination requires a method that will not only emphasize abnormal masses but will also tend to subtract the multiple and variable masses that make up the normal breast. For that reason experienced examiners have always used finger
The Need for a Consensus Next-generation Sequencing Panel for Mature Lymphoid Malignancies
Authors: Pierre Sujobert, Yannick Le Bris, Laurence de Leval, Audrey Gros, Jean Philippe Merlio, Cedric Pastoret, Sarah Huet, Clémentine Sarkozy, Frédéric Davi, Mary Callanan, Catherine Thieblemont, David Sibon, Vahid Asnafi, Claude Preudhomme, Philippe Gaulard, Fabrice Jardin, Gilles Salles, Elizabeth Macintyre
Journal: HemaSphere (2018)
Correction: Cell death induced by cytotoxic CD8+ T cells is immunogenic and primes caspase-3–dependent spread immunity against endogenous tumor antigens
Authors: Melissa J Kasiewicz, Michael J McNamara, Joshua M Walker, Annah S Rolig, Daniel C Rose, Ian F Hilgart-Martiszus
Journal: Journal for ImmunoTherapy of Cancer (2020)

Cell death induced by cytotoxic
The Toxemias of Pregnancy.
Journal: JAMA (1952)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Missing Reference Citation
Authors: Xiaoyu Nie, Soeren Mattke, Hangsheng Liu, Quoc-Dien Trinh
Journal: JAMA Internal Medicine (2016)

explain an error that occurred in our Research Letter, "Differences in Prostate-Specific Antigen Testing Among Urologists and Primary Care Physicians Following the 2012 USPSTF Recommendations," 1 published in the April 2016 issue of JAMA Internal Medicine.Following a query to the editor and statistical review regarding the odds ratio reported in the Figure of that article, we reconducted the statistical analysis to provide adjusted odds ratios.This new analysis resulted in corrections to the text in the Results and Discussion section and to the Figure.The adjusted odds ratios are consistent with the original observed and reported findings; that is, there was a decrease in prostate-specific antigen testing among primary care physicians (n = 1109) and urologists (n = 113) following the release of the USPSTF recommendations.The significance of those results remains the same: the decrease among primary care physicians was statistically significant, while the decrease among urologists was not.However, the result of the interaction analysis was no longer significant, most likely owing to the small number of urologists.We have thoroughly reviewed our analyses, and no other errors were found.We apologize to the readers and editors of the journal for any confusion this may have caused.
Oral Contraceptives and Immune Responses
Journal: JAMA (1969)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vets may be compensated.
Journal: Environmental Health Perspectives (1994)

a a corresponding flux from the ocean to the atmosphere.This effect might lessen or negate the benefits to stratospheric ozone from a reduction in anthropogenic emis- sions of methyl bromide.In terms of costs to society from the ban, the California Department of Pesticide Regulation estimates growers in its state stand to lose $340 million per year in crop damage.Duafala says no single alternative exists that will replicate the range of uses of methyl bromide.He says there are nematicides (1,3-dichloropropene) and fungicides (methyl isothio- cyanate) that effectively perform some of the functions but that these are not as versatile as methyl bromide.Bill Thomas, methyl bromide program coordinator for the EPA, agrees that there is no single alternative for methyl bromide, but asserts that the ban-phased in over a period of seven years-will allow for the development of alternatives."The cost of finding alternatives is an issue, but not a monumental barrier," Thomas says.
Identification of a new candidate mutation, G1629R, in a family with type 2A von Willebrand disease
Authors: Pilar Casaña, Francisco Martínez, Saturnino Haya, José A. Aznar
Journal: American Journal of Hematology (1999)

Type 2A is a qualitative variant of von Willebrand disease (vWD) characterized by a reduced platelet-dependent function, associated with an absence of large multimers. A G5135A transition, resulting in a glycine to arginine substitution at the codon 1629 of the von Willebrand factor, was identified by automated sequencing in one type 2A vWD Spanish patient. To detect this new candidate mutation a modified primer that creates a DdeI restriction site when the mutation is present was designed. This approach allowed detection of the mutation in the other three patients from the same family. On the other hand, the fact that this new mutation was not found in the 110 normal alleles screened further supports their causal relationship with the disease. Am. J. Hematol. 60:309–310, 1999. © 1999 Wiley-Liss, Inc.
Travelers' diarrhea
Authors: M. H. Merson
Journal: JAMA (1975)

MANY epidemiologic and laboratory studies of travelers' diarrhea have been conducted, but because of variations in study design and geographic location, it is not known whether the etiology and source of the affliction are the same worldwide. The clinical syndrome generally follows a typical pattern. Within ten days of arrival to a new country, and usually within the first week, the traveler experiences the acute onset of watery diarrhea, with sometimes up to 10 or 20 episodes a day. This diarrhea is frequently accompanied by additional symptoms, including abdominal cramps, nausea, anorexia, vomiting, malaise, chills, or fever. The syndrome usually lasts one to five days and is self-limited; in severe cases, it can last a week or more. During the last 50 years, the lay press and various medical authors have offered many hypotheses to explain the cause of travelers' diarrhea. A potpourri of noninfectious causes have been proposed, none
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1891)

(FROM OUR OWN CORRESPONDENT.) With the June meeting the New York County Medical Association concluded its labors for the present season. After the scientific exercises, the members adjourned to the supper-room below, where they made merry on strawberries and ice-cream, served in place of the ordinary collation, and were entertained with short congratulatory speeches by the President, Dr. McLeod, and others. Among the speakers were Dr. Truax and ex-Presidents Harrison and Shrady, and the latter, in his genial way, related a number of reminiscences of medical life in New York in former days. The Association still continues in a very gratifying condition of prosperity, and, notwithstanding the fact that an unusually large number of its members have been removed by death during the past year, it adjourns for the summer with 648 names on its roll, as against 531 at the same time last year. At this June meeting the
J Obstet &amp;amp; Gynaec Brit Commonwlth, London
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
BACTERIALLY TAINTED MONEY
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Usefulness of bone densitometry in postmenopausal women with clinically diagnosed vertebral fractures
Authors: K Moss
Journal: Annals of the Rheumatic Diseases (2002)

Soluble TNF receptor treatment does not affect raised TGFβ levels in RAWe read with interest the report by Drynda et al demonstrating that treatment of rheumatoid arthritis (RA) with anti-tumour necrosis factor α (anti-TNFα) induces subtle changes in the cytokine network such as down regulation of the proinflammatory cytokine interleukin 6 (IL6), but does not affect the persistently high plasma levels of transforming growth factor β (TGFβ). 1 Furthermore, they suggest that the latter finding indicates the existence of as yet unknown mechanisms for TGFβ overexpression in RA that may predispose a patient to severe infections and altered tumour defence.Complementary to the observations noted above are our findings using DNA microarray in patients with RA treated with TNF antagonists as compared with patients with RA treated with methotrexate and healthy controls. 2A total of 12 000 genes were analysed (human genome U 95 A Array-Affimetrix) and a variety of gene functions, including apoptosis, transcription factors, cell survival, antigen presentation, cartilage degradation, B and T cell function, intracellular signals, transcription genes, adhesion molecules, inflammatory mediators, clotting factors, HLA class II molecules, oncogenes, cytokine production, and cytokine receptor expression, were altered (up or down regulated) in the group receiving TNF antagonists.Of interest, several proinflammatory cytokine receptors including interferon γ, TNF, IL10, and TGFβ were found to be down regulated.Therefore, pathway signalling of these cytokines including TGFβ may be impaired if their receptors are down regulated.Altered expression of these genes' function, alone or in combination, may have an impact on the predisposition to infection and tumour defence.Such is the case for the induced TNFα inhibitor down regulation in the expression of C9, B and T cell functions, signalling cascade (↓ Jun B), adhesion molecules, heat shock proteins, and antigen presentation, and the predisposition to infection.Likewise, TNF antagonists also regulate the expression of oncogenes, such as Jun B, c-myc, fos and ras, which may have an impact on tumour defence.Therefore, our study with DNA microarray confirms and expands the immunomodulatory functions of TNF antagonists.Data, however, seem to suggest that the increased predisposition to develop infection and altered tumour defence may not be related to increased plasma levels of TGFβ because its receptors are down regulated, but rather to dysregulation of gene expression of other molecules induced by, the TNF antagonists.
Cardiac Arrest
Authors: Vance Lauderdale
Journal: JAMA (1961)

<h3>To the Editor:—</h3> The article "Cardiac Arrest in Obstetrics" by Gold and his associates (<i>JAMA</i><b>175</b>:1065 [March 25] 1961) invites comment. I feel that their use of the term "cardiac arrest" does more to becloud our understanding of the mechanisms of maternal death in obstetrics than it does to clarify it. I think the authors have fallen into a semantic trap in their statement that cardiac arrest seems to be on the increase. It is true that this diagnosis appears more often on death certificates than it did in former years, but there is no evidence of a significant change in the pattern of causes of death. Those cases in which the cause of death is unknown should be so labelled. The use of the term "cardiac arrest" in an article such as this will encourage a trend which in my opinion has already gone too far. To label
Real-world treatment patterns and outcomes in hepatorenal syndrome: results from a retrospective chart review study in the United Kingdom
Authors: Kevin Moore, Khurram Jamil, Katharina Verleger, Linlin Luo, Nehemiah Kebede, Marieke Heisen, Shelby Corman, Rachel Bakker, Christine Mai, Nisreen Shamseddine, Xingyue Huang
Journal: Journal of Hepatology (2020)
ACKNOWLEDGMENT
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Unusual osseous metastases of hepatoma
Authors: E. J. Reichbach
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal